European Medicines Agency (EMA) with the European Commission; national competent authorities in each member state
Is Tesamorelin legal in European Union?
Not approvedNot authorised in the EU: the Egrifta application was withdrawn in 2012
Not approved as a medicine here.
Tesamorelin has no EU-wide authorisation. The company Ferrer Internacional withdrew its application for Egrifta (excess abdominal fat in HIV lipodystrophy) from CHMP review on 21 June 2012. No centralised authorisation has been granted since. Tesamorelin is also on the WADA 2026 Prohibited List as a growth-hormone-releasing factor (S2.2.4).
Last verified 2026-09-29 · how we verify
Tesamorelin elsewhere
Sources (3)
- 01Egrifta: application withdrawn (tesamorelin)European Medicines Agency · 2012-07-18 · accessed 2026-09-29
- 02EMA medicines data (JSON report): human and veterinary medicines, with authorisation statusEuropean Medicines Agency · 2026-09-29 · accessed 2026-09-29
- 03The 2026 Prohibited ListWorld Anti-Doping Agency · 2025-09 · accessed 2026-09-29